New production facility in the United States delivers its first pharmaceutical lipid batch, strengthening the development and large-scale manufacturing of advanced medicines
Lafayette, Indiana, 12 November 2026 – Pharmaceutical manufacturing is entering a new phase as researchers and companies explore advanced ways to develop and deliver medicines. Technologies such as messenger RNA (mRNA), gene therapy, and cancer immunotherapy are creating demand for specialized ingredients that can help medicines reach the right cells in the body. Supporting this progress, Evonik has produced its first batch of pharmaceutical lipids at its new Lipid Innovation Center (LINC) in Lafayette, Indiana, marking an important step in expanding its pharmaceutical manufacturing capabilities.
The new facility is located at Evonik's Tippecanoe site and is designed to manufacture pharmaceutical-grade lipids used in advanced drug delivery systems. With support from the US government, the center will help strengthen domestic production capabilities and support the pharmaceutical supply chain. The company expects the facility to reach its full production capacity by mid-2027.
The first product manufactured at the center is PhytoChol, a cholesterol ingredient derived from non-animal sources. It is an important component used in lipid nanoparticles (LNPs), which help protect and transport delicate genetic material into cells. This delivery method plays a major role in mRNA-based medicines and other nucleic acid therapies.
Lipid nanoparticles gained wider attention through their use in COVID-19 vaccines. However, their applications extend beyond vaccines. They are also being explored for cancer treatments, gene therapies, and medicines designed to address several complex diseases. As research in these areas advances, demand for reliable and high-quality lipid ingredients is expected to increase. The global lipid nanoparticle market is projected to reach an estimated $2.7 billion by 2034.
Evonik's Lipid Innovation Center has been designed to support different lipid types, manufacturing processes, and pharmaceutical products. Its flexible production capabilities will allow the company to serve customers working across various stages of drug development. This includes early research, clinical trials, and commercial manufacturing, where consistent product quality and reliable supply are essential.
The facility is also part of Evonik's wider global network for lipid-based drug delivery technologies. The network brings together expertise in lipid chemistry, LNP formulation, process development, sterile manufacturing, and regulatory requirements. Its Vancouver laboratories focus on developing LNP formulations and supporting clinical manufacturing, while the Birmingham facility in Alabama is expected to handle late-stage clinical and commercial processes. Additional production and research capabilities are supported by sites in Germany and the United States.
This connected approach is intended to make the transition from laboratory research to large-scale pharmaceutical production more efficient. By coordinating different stages of development and manufacturing, Evonik aims to help pharmaceutical companies bring advanced medicines closer to patients while maintaining consistent quality.
The first production batch represents an important milestone in the company's investment in advanced pharmaceutical manufacturing. As demand for RNA-based medicines and targeted drug delivery technologies grows, dependable access to specialized ingredients will become increasingly important. Through its new center, Evonik is positioning itself to support the next generation of pharmaceutical innovation and the expanding market for advanced therapies.